Warning! GuruFocus detected
1 Severe warning sign
with 47N0.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Citius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US17322U2078
Description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.37 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.7 | |||||
| 3-Year EPS without NRI Growth Rate | -1 | |||||
| 3-Year FCF Growth Rate | 34.3 | |||||
| 3-Year Book Growth Rate | -24.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 25.16 | |||||
| 14-Day RSI | 28.9 | |||||
| 6-1 Month Momentum % | -70.09 | |||||
| 12-1 Month Momentum % | -81.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.41 | |||||
| Quick Ratio | 0.09 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.5 | |||||
| Shareholder Yield % | -17.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -51.49 | |||||
| ROA % | -37.96 | |||||
| ROIC % | -49.76 | |||||
| 3-Year ROIIC % | -57.48 | |||||
| ROC (Joel Greenblatt) % | -1399.53 | |||||
| ROCE % | -49.87 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 30.48 | |||||
| PB Ratio | 0.18 | |||||
| EV-to-EBIT | -0.32 | |||||
| EV-to-Forward-EBIT | 1.55 | |||||
| EV-to-EBITDA | -0.32 | |||||
| EV-to-Forward-Revenue | 1.09 | |||||
| EV-to-FCF | -0.51 | |||||
| Earnings Yield (Greenblatt) % | -312.5 | |||||
| FCF Yield % | -201.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.336 | ||
| Beta | 0.89 | ||
| 3-Year Sharpe Ratio | -0.53 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 90.16 | ||
| 14-Day RSI | 28.9 | ||
| 14-Day ATR (€) | 0.001281 | ||
| 20-Day SMA (€) | 3.29 | ||
| 12-1 Month Momentum % | -81.96 | ||
| 52-Week Range (€) | 3.1225 - 23.325 | ||
| Shares Outstanding (Mil) | 8.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Citius Pharmaceuticals Inc Frequently Asked Questions
What is Citius Pharmaceuticals Inc(FRA:47N0)'s stock price today?
The current price of FRA:47N0 is €3.29. The 52 week high of FRA:47N0 is €23.33 and 52 week low is €3.12.
When is next earnings date of Citius Pharmaceuticals Inc(FRA:47N0)?
The next earnings date of Citius Pharmaceuticals Inc(FRA:47N0) is 2025-05-14 Est..
Does Citius Pharmaceuticals Inc(FRA:47N0) pay dividends? If so, how much?
Citius Pharmaceuticals Inc(FRA:47N0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers